Sustainability of first-line antiretroviral regimens: Findings from a large HIV treatment program in Western Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 53, Issue 2, 2010, Pages 254-259

  Braitstein, Paula ^a,b,c,d   Ayuo, Paul ^b,c   Mwangi, Ann ^b,c,d,e   Wools Kaloustian, Kara ^a,b,c   Musick, Beverly ^a,c   Siika, Abraham ^a,b,c   Kimaiyo, Sylvester ^b,c  

^a INDIANA UNIVERSITY   (United States)

^b MOI UNIVERSITY   (Kenya)

^c ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE AMPATH   (Kenya)

^d REGENSTRIEF INSTITUTE   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

Adverse effects; Africa; Antiretroviral; Treatment durability; Treatment failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE MORAL JUDGMENT; TRAVEL;

EID: 75649116801     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b8f26e     Document Type: Article

References (14)

1. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;67:817-824.
2. Wools-Kaloustian K, Kimaiyo S, Diero L, et al. Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. Aids. 2006;20:41-48.
3. World Health Organization, Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector, W.H. Organization, Editor. 2008, World Health Organization: Geneva.
4. Huffam SE, Srasuebkul P, Zhou J, et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med. 2007; 8:465-471.
5. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India. J Acquir Immune Defic Syndr. 2006;41:53-58.
6. Hawkins C, Achenbach C, Fryda W, et al. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007;45:304-310.
7. Einterz RM, Kimaiyo S, Mengech HN, et al. Responding to the HIV pandemic: the power of an academic medical partnership. Acad Med. 2007;82:812-818.
8. Tierney WM, Rotich JK, Hannan TJ, et al. The AMPATH medical record system: creating, implementing, and sustaining an electronic medical record system to support HIV/AIDS care in western Kenya. Medinfo. 2007;12:372-376.
9. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91:301-308.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents-November 3, 2008. Washington, DC. Department of Health and Human Services, United States. p. 1-139.
11. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Geneva, Switzerland: 2006 [cited 2009 June 22]; Available from: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.
12. Kumarasamy N, Solomon S, Chaguturu SK, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. Aids. 2003;17:2267-2269.
13. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104. (Pubitemid 46390846)
14. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064.